Investigating how gut bacteria can enhance immune response against liver cancer
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer
This study is looking at how the bacteria in our gut can help treat liver cancer by using a special mouse model, and it hopes to find ways to boost the immune system and improve treatment results for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-11076418 on NIH RePORTER |
What this research studies
This research explores the role of gut microbiota in the treatment of hepatocellular cancer (HCC) by using a novel mouse model that mimics human disease. The study examines how an antibiotic cocktail can influence the immune response and tumor growth in HCC. By restoring the function of specific immune cells and enriching beneficial gut bacteria, the research aims to improve therapeutic outcomes for patients with liver cancer. The findings could lead to new strategies for enhancing the effectiveness of existing cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular cancer who may benefit from enhanced immune therapies.
Not a fit: Patients with other types of cancer or those who do not have hepatocellular cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with hepatocellular cancer by enhancing their immune response.
How similar studies have performed: Other research has shown promising results in manipulating gut microbiota to improve cancer treatment outcomes, indicating that this approach may be viable.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Staveley-O'carroll, Kevin Finnbar — University of Connecticut Sch of Med/dnt
- Study coordinator: Staveley-O'carroll, Kevin Finnbar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.